DDInter596 DDInter1676
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Doxorubicin {u} (Compound) treats {v} (Disease) stomach cancer
Doxorubicin {u} (Compound) binds {v} (Gene) AKR1A1
Doxorubicin {u} (Compound) upregulates {v} (Gene) P4HA2
Doxorubicin {u} (Compound) is included by {v} (Pharmacologic Class) Anthracyclines
Doxorubicin {u} (Compound) downregulates {v} (Gene) TSKU
Doxorubicin {u} (Compound) causes {v} (Side Effect) Mucous membrane disorder
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) CBR3
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) ABCC10
Doxorubicin (Compound) resembles Daunorubicin (Compound)
Doxorubicin (Compound) treats stomach cancer (Disease)
Doxorubicin (Compound) binds AKR1A1 (Gene)
Doxorubicin (Compound) upregulates P4HA2 (Gene)
Doxorubicin (Compound) is included by Anthracyclines (Pharmacologic Class)
Doxorubicin (Compound) downregulates TSKU (Gene)
Doxorubicin (Compound) causes Mucous membrane disorder (Side Effect)
Doxorubicin (Compound) binds CBR3 (Gene) and Doxorubicin (Compound) downregulates CBR3 (Gene)
Doxorubicin (Compound) binds ABCC10 (Gene) and Doxorubicin (Compound) upregulates ABCC10 (Gene)